Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
30 Juin 2023 - 10:42PM
Sientra, Inc. (NASDAQ:SIEN) (“Sientra” or the “Company”), a
medical aesthetics company uniquely focused on plastic surgeons,
today announced that on June 27, 2023, the Company approved
equity award grants under the Sientra Inc. Inducement
Plan to 20 new employees.
The new employees were granted restricted stock units
representing a total of 85,750 shares of common stock. The
restricted stock units will vest in time-based installments
beginning on the grant date. In each case, the vesting of shares is
contingent upon the recipient’s continued service with the Company
through each vesting date.
The grants were made as an inducement that was a material
component of each person’s compensation and subsequent acceptance
of employment with the Company and were granted as employment
inducement awards pursuant to NASDAQ Listing Rule 5635(c)(4)
approved by the Compensation Committee.
About Sientra
Headquartered in Irvine, California, Sientra is a medical
aesthetics company exclusively focused on plastic surgery. The
Company mission is to offer proprietary innovations and
unparalleled partnerships that radically advance how plastic
surgeons think, work and care for their patients. Sientra has
developed a broad portfolio of products with technologically
differentiated characteristics, supported by independent laboratory
testing and strong clinical trial outcomes. The Company’s product
portfolio includes its Sientra round and shaped breast implants,
the first fifth-generation breast implants approved by the FDA for
sale in the United States, its ground-breaking AlloX2® breast
tissue expander with patented dual-port and integral drain
technology, the Viality™ with AuraClens™ enhanced viability fat
transfer system, the SimpliDerm® Human Acellular Dermal
Matrix, and BIOCORNEUM® the #1 performing, preferred and
recommended scar gel of plastic surgeons (*).
Sientra uses its investor relations website to publish important
information about the Company, including information that may be
deemed material to investors. Financial and other information about
Sientra is routinely posted and is accessible on the Company’s
investor relations website at www.sientra.com.
(*) Data on file
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, based on management’s current assumptions and expectations
of future events and trends, which affect or may affect the
Company’s business, strategy, operations or financial performance,
and actual results may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are made only as of the date of this
release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’
‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’
‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of
those terms, and similar expressions that convey uncertainty of
future events or outcomes are intended to identify estimates,
projections, and other forward-looking statements. Forward-looking
statements may include information concerning the Company’s
possible or assumed future results of operations, including
descriptions of the Company’s revenues, profitability, outlook, and
overall business strategy, the Company’s ability and timing to
successfully integrate new products into its existing operations,
the clinical performance of the Company’s products, the reception
of plastic surgeons to the Company’s products, and the Company’s
ability to capture additional market share and customer accounts in
the plastic surgery market. Such statements are subject to risks
and uncertainties, including the positive reaction from plastic
surgeons and their patients to the Company’s products, the ability
to meet consumer demand, including any potential supply issues
resulting from the COVID-19 pandemic or the war in Ukraine, the
growth of the plastic surgery market and breast procedures, and the
ability of the Company to execute on its commercial, marketing,
research and development and regulatory plans. Additional factors
that could cause actual results to differ materially from those
contemplated in this press release can be found in the Risk Factors
section of Sientra’s public filings with the Securities and
Exchange Commission. All statements other than statements of
historical fact are forward-looking statements. The words
‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’
‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’
‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar
expressions that convey uncertainty of future events or outcomes
are intended to identify estimates, projections, and other
forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, and such estimates,
projections, and other forward-looking statements speak only as of
the date they were made, and, except to the extent required by law,
the Company undertakes no obligation to update or review any
estimate, projection or forward-looking statement. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business.
Investor Relations ContactAman R. Patel,
CFAaman.patel@westwicke.com
Source: Sientra, Inc.
Sientra (NASDAQ:SIEN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sientra (NASDAQ:SIEN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024